Case Reports

Concurrent herpetic hypertensive anterior uveitis and cytomegalovirus retinitis in a non-HIV patient with melanoma differentiation-associated gene-5 dermatomyositis: intravenous immunoglobulin comes to the rescue

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 21 April 2026
0
Views
0
Downloads

Authors

Melanoma differentiation-associated gene 5 dermatomyositis (MDA-5 DM) is a rare subtype of dermatomyositis. Cytomegalovirus (CMV) retinitis is an opportunistic ocular infection that has historically been linked to HIV infection. Herpes simplex virus (HSV) uveitis is caused by the reactivation of the varicella zoster virus. We present the case of a 69-year-old woman diagnosed with aggressive MDA-5 DM associated with interstitial lung disease, who received multiple immunosuppressive therapies and subsequently developed left eye CMV retinitis and right eye acute herpetic, hypertensive, anterior uveitis with dendritic keratitis. After the diagnosis of MDA-5 DM, she was treated with glucocorticoids (GC), followed by rituximab and triple therapy (cyclosporin, cyclophosphamide, and GC); however, she did not improve and multiple adverse effects occurred. The patient then started tofacitinib (TOF) and improved. While being on TOF, she developed right eye acute herpetic, hypertensive, anterior uveitis followed by left eye CMV retinitis. TOF was stopped, and the patient started oral acyclovir and intravenous and intravitreal ganciclovir, which was later changed to maintenance therapy with oral valganciclovir. Cyclical intravenous immunoglobulin (IVIG) administration was started, resulting in an overall improvement in disease activity associated with MDA-5 DM. This case underscores the uncommon link between CMV retinitis in a non-HIV patient and HSV anterior uveitis in a patient undergoing immunosuppressive therapy and the challenge of treating MDA-5 DM with IVIG, which led to favorable results.

Downloads

Download data is not yet available.

Citations

Ruppel T, Forbes Kaprive J, Heydari-Kamjani M, Kesselman MM. Anti-melanoma differentiation-associated gene 5 (Anti-MDA5) dermatomyositis: a case presentation. Cureus 2022; 14: e23102.
Hirsch S, Pöhler GH, Seeliger B, Prasse A, Witte T, Thiele T. Treatment strategies in MDA5-positive clinically amyopathic dermatomyositis: a single-center retrospective analysis. Clin Exp Med 2024; 24: 37.
Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int 2021; 41: 1021-36.
Kobayashi R, Hashida N. Overview of cytomegalovirus ocular diseases: retinitis, corneal endotheliitis, and iridocyclitis. Viruses 2024; 16: 1110.
Romero-Bueno F, del Campo PD, Trallero-Araguás E, Ruiz-Rodríguez J, Castellvi I, Rodriguez-Nieto M, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 2020; 50: 776-90.
Ge Y, Li S, Tian X, He L, Lu X, Wang G. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol 2021; 40: 2311-7.
Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis—associated interstitial lung disease. N Engl J Med 2019; 381: 291-3.
Song MK, Karavellas MP, MacDonald JC, Plummer DJ, Freeman WR. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina 2000; 20: 151-5.
Kuo IC, Kempen JH, Dunn JP, Vogelsang G, Jabs DA. Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am J Ophthalmol 2004; 138: 338-46.
Munro M, Yadavalli T, Fonteh C, Arfeen S, Lobo-Chan AM. Cytomegalovirus retinitis in HIV and non-HIV individuals. Microorganisms 2019; 8: 55.
Padda IS BR, Parmar M. Tofacitinib. Treasure Island, FL, USA: StatPearls Publishing; 2023.
Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol 2017; 69: 1960-8.
Yanagisawa K, Ogawa Y, Hosogai M, Todokoro D, Mitsui T, Yokohama A, et al. Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy. J Infect Chemother 2017; 23: 572-5.
Cugley DR, Darby J, Lim LL. Tofacitinib-associated cytomegalovirus retinitis. Rheumatology 2020; 59: e35-7.
Gupta P, Kharbanda R, Lawrence A, Gupta L. Systemic flare and cutaneous ulceration following cytomegalovirus infection in a patient with anti-melanoma differentiation-associated protein 5 (MDA5) associated myositis: diagnostic challenge during the time of coronavirus disease (COVID-19) pandemic. Egypt Rheumatol 2021; 43: 271-4.
Tiniakou E, Mecoli CA, Kelly W, Albayda J, Paik J, Adler B, et al. Anti-MDA5-positive dermatomyositis and remission in a single referral centre population. Clin Exp Rheumatol 2023; 41: 309-15.
Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol 2017; 44: 319-25.
Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology 2020; 95: e70-8.
Bhandari S, Zickuhr L, Baral MR, Bhalla S, Jones H, Bucelli R, Sen D. A review of MDA-5 dermatomyositis and associated interstitial lung disease. Rheumato 2024; 4: 33-48.
Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease modifying antirheumatic drugs. Arthritis Care Res 2015; 67: 1671-8.
Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicentre prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 2020; 72: 488-98.
Tseng C, Satoh M, Chen Y. AB0697 Dramatic reduction of mortality rate by tofacitinib in anti-MDA-5 antibody-positive patients with rapidly progressive interstitial lung disease. London, UK: BMJ Publishing Group Ltd; 2022.
Wang LM, Tang QH, Zhang L, Liu SY, Zhang PP, Zhang X, et al. Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Rheumatology 2022; 61: 3704-10.
Shapira Y, Mimouni M, Vishnevskia-Dai V. Cytomegalovirus retinitis in HIV-negative patients – associated conditions, clinical presentation, diagnostic methods and treatment strategy. Acta Ophthalmol 2018; 97: e761-7.
Billet AC, Barba T, Coutant F, Fabien N, Perard L, Sève P, et al. Infection risk in patients with dermatomyositis associated with anti-MDA5 antibodies: a historical cohort study. Biomedicines 2022; 10: 3176.

How to Cite



1.
Concurrent herpetic hypertensive anterior uveitis and cytomegalovirus retinitis in a non-HIV patient with melanoma differentiation-associated gene-5 dermatomyositis: intravenous immunoglobulin comes to the rescue. Reumatismo [Internet]. 2026 Apr. 21 [cited 2026 Apr. 22];. Available from: https://www.reumatismo.org/reuma/article/view/1826